View Mobile Site

Ask the Expert

Signal Photos


Swedish national champ wins Amgen Women's Criterium cycling race

Pro cycling event part of Tour of California's Stage 1

Posted: February 18, 2009 3:38 p.m.
Updated: February 15, 2009 10:00 p.m.

SANTA ROSA, Calif., February 15, 2009 - Welcomed by thousands of fans lining the streets of Santa Rosa, Stage 1 of the 2009 Amgen Tour of California featured the second-annual Women's Criterium presented by the Redwood Regional Breast Center.

Emilia Fahlin (SWE), the youngest member of Team Columbia-Highroad, won the criterium race with an impressive performance besting an outstanding field of international competitors.

The first event of the 2009 season on the National Racing Calendar (NRC), the Women's Criterium took part over portions of the Stage 1 men's finishing circuit in Santa Rosa.

The second-annual event consisted of a field of 88 riders competing for more than $15,000 in prizes. Set as a category Pro 1,2 race and with a limit of eight riders per team, the Amgen Tour of California Women's Criterium showcased some of the world's top professional women's cycling teams, including defending champion Brooke Miller of Team TIBCO, who finished 15th overall.

"The 2009 Amgen Tour of California Women's Criterium was a huge success," said Laura Charameda, race director, Amgen Tour of California Women's Criterium. "We had an amazing representation from the top women's teams. With the support of AEG, which believes in building great events for both men and women, I look forward to the opportunity to help grow this event into the most important race in the world for professional women cyclists."

Emilia Fahlin, overall winner of the Women's Criterium and current National Champion of Sweden, took several important wins in the 2008 season, including the Merced Criterium and Merco Cycling Classic Road Race. Fahlin also took a stage win in the 2008 Redlands Bicycle Classic. In 2007, she took second place in the Sparkassen Giro Bochum.

"When I was here last year, I finished third," said Fahlin, winner of the second-annual Amgen Tour of California Women's Criterium. "I really enjoyed the race last year with the big crowds, so I wanted to do better. Getting to win here was really fun and great way to start the season; very motivating."

Rounding out the top three were Lauren Tamayo (USA) of Team TIBCO in second and Rachel Lloyd (USA) of Proman in third. Tamayo took first in the 2008 Women's International Challenge and the 2008 Atlanta 10K Classic. Lloyd won the 2008 Single Speed World Championship Mountain Bike Race.

America's most successful cycling race, the Amgen Tour of California, is a more than 750-mile, nine-day stage race, modeled after the Tour de France. One of the nation's largest and most recognized annual sports events, this international, world-class cycling road race features 17 elite professional teams and athletes from around the world, competing for the highest prize purse of any cycling race in North America.

The Amgen Tour of California brings the drama and excitement of a professional cycling stage race to the California coast for a fourth year in 2009, from Feb. 14-22.

"Returning to Santa Rosa for the second-annual Amgen Tour of California Women's Criterium was an obvious choice after the incredible turnout last year," said Andrew Messick, president, AEG Sports, presenter of the race. "There are a lot of passionate cycling fans watching the 2009 Amgen Tour of California, so we wanted to utilize that opportunity to showcase the amazing talent of these professional women cyclists as well. We remain committed to presenting women's cycling and will look for ways to help promote and grow women's cycling in the coming months and years."

About the Amgen Tour of California
The largest cycling event in America, the Amgen Tour of California is a Tour de France-style cycling road race, presented by AEG, that challenges the world's top professional cycling teams to compete along a demanding course. Building on last year's third-annual stage race, which attracted 1.6 million spectators, the 2009 Amgen Tour of California will be expanded to cover more than 750 miles over nine days from February 14-22, 2009. For more information on the 2009 Amgen Tour of California, as well as a nightly viewing schedule on VERSUS, please visit

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about Amgen's pioneering science and vital medicines, visit To learn more about Amgen's Breakaway from Cancer initiative, visit

About AEG
AEG is one of the leading sports and entertainment presenters in the world. AEG, a wholly owned subsidiary of The Anschutz Company, owns or controls a collection of companies including facilities such as STAPLES Center, The Home Depot Center, Sprint Center, The O2, Nokia Theatre L.A. LIVE and NOKIA Theatre Times Square; sports franchises including the Los Angeles Kings (NHL), two Major League Soccer franchises, a Women's Professional Soccer league team, the Los Angeles Sol, two hockey franchises operated in Europe, management of privately held shares of the Los Angeles Lakers, the ING Bay to Breakers foot race and the Amgen Tour of California cycling road race; AEG Live, the organization's live-entertainment division, is a collection of companies dedicated to all aspects of live contemporary music performance, touring and a variety of programming and multi-media production. For more information, visit AEG today at


Most Popular Articles

There are no articles at this time.
Commenting not available.
Commenting is not available.


Powered By
Morris Technology
Please wait ...